Prostate-specific antigen (PSA) is a protein produced exclusively by certain tissues of the prostate gland, which is a male-specific sex gland. PSA helps to liquefy semen and keep it watery.
Most of this protein is eliminated from the body through the semen; however, small measures of this antigen enters the blood stream and can be found in the blood serum.
PSA is an established biological marker or a cancer tumor marker because it enables disease–detection, ranging from benign conditions such as prostatitis and prostate gland hypertrohy to cancer of the prostate.
Research is being carried out to improvise the PSA test and make it more reliable and sensitive.
Prosate cancer is the commonest cancer that affects older men. It causes a rise in the level of PSA in the blood. This change in the PSA levels can be detected by a simple blood test, known as the PSA test.
Although PSA is not specific enough to be the final determinant of prostate cancer, elevated levels of PSA is considered serious enough to warrant further investigations.
PSA can either be attached to another compound or may exist by itself:
- Attached PSA: This is a type of PSA which is complexed or attached to the protease inhibitor, alpha –1 antichymotrypsin
- Free PSA: This PSA is free and is not complexed to any molecule
- Total PSA: This is the sum of both the attached and the free form of the PSA
Individuals with prostate cancer tend to have low percent of free PSA compared to those with the benign disease.
Normal concentration of PSA is 0-4 nanogram/ml. This concentration can vary with age. Normally, the prostate gland enlarges in older men and this leads to the increased production of PSA.
Age-specific PSA levels are given below:
- 40 – 49 yrs - 2.5ngms/ml
- 50 – 59 yrs - 3.5 ngms /ml
- 60 – 69 yrs - 4.5ngms /ml
- 70 – 79 yrs - 6.5 ngms /ml
PSA levels not only rise in the case of prostate cancers but also in the case of many conditions of the prostate such as:
- Benign prostatic hypertrophy (BPH)
- Prostate bladder or kidney infections
- Poor blood supply to the prostate
- Urinary retention
In many cases, PSA is also carried out to check recurrence in a person with prostate cancer. Increased levels of PSA is definitely indicative of recurrence although a single PSA test may not be sufficient to confirm it. Once the levels rise the doctors will ask for further tests to be carried out to confirm the cancer!
It may be interesting to note that the PSA levels increases much before the clinical symptoms of prostate cancer manifest themselves and hence they provide a window of opportunity to cure the cancer before it spreads to other parts of the body. They are also useful in the follow up of the patients who has been treated. Any persistent elevation is considered as recurrence of the cancer.
Sometimes PSA tests reveal small tumors that are not life threatening. However this will prompt unnecessary treatment initiation. There are also several cases of false positives reported.
Latest Publication and Research on Prostate Specific Antigen [PSA]Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. - Published by PubMed
Medical Management of Lower Urinary Tract Symptoms in Men with Benign Prostatic Enlargement. - Published by PubMed
Clinical Progression, Acute Urinary Retention, Prostate-Related Surgeries, and Costs in Patients with Benign Prostatic Hyperplasia Taking Early Versus Delayed Combination 5a-Reductase Inhibitor Therapy and a-Blocker Therapy: A Retrospective Analysis. - Published by PubMed
Locally Advanced and Metastatic Prostate Cancer Treated with Intermittent Androgen Monotherapy or Maximal Androgen Blockade: Results from a Randomised Phase 3 Study by the South European Uroncological Group. - Published by PubMed
Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08). - Published by PubMed